Kolltan Pharmaceuticals Secures $60,000,000 New Funding

  • Feed Type
  • Date
    3/20/2014
  • Company Name
    Kolltan Pharmaceuticals
  • Mailing Address
    300 George St. New Haven, CT 06511 USA
  • Company Description
    Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need.
  • Website
    http://www.kolltan.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $60,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy